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ABSTRACT
ABCG2 encodes the mitoxantrone resistance protein (MXR; breast
cancer resistance protein), an ATP-binding cassette (ABC) efflux
membrane transporter. Computational analysis of the ∼300 kb
region of DNA surrounding ABCG2 (chr4:88911376-89220011,
hg19) identified 30 regions with potential cis-regulatory capabilities.
These putative regulatory regionswere tested for their enhancer and
suppressor activity in a human liver cell line using luciferase reporter
assays. The in vitro enhancer and suppressor assays identified four
regions that decreased gene expression and five regions that
increased expression >1.6-fold. Four of five human hepatic in vitro
enhancers were confirmed as in vivo liver enhancers using the
mouse hydrodynamic tail vein injection assay. Two of the in vivo liver
enhancers (ABCG2RE1 and ABCG2RE9) responded to 17b-estradiol
or rifampin in human cell lines, and ABCG2RE9 had ChIP-seq
evidence to support the binding of several transcription factors
and the transcriptional coactivator p300 in human hepatocytes. This
study identified genomic regions surrounding human ABCG2 that
can function as regulatory elements, some with the capacity to alter
gene expression upon environmental stimulus. The results from this
research will drive future investigations of interindividual variation in
ABCG2 expression and function that contribute to differences in
drug response.
Introduction
The mitoxantrone resistance protein (MXR; breast cancer resistance
protein/ABCG2) is an efflux membrane transporter that is expressed
apically in selected tissues, including liver, kidney, breast, and intestine
(Robey et al., 2009). Transport activity, tissue distribution, and cellular
localization of MXR suggest that it plays a pivotal role in endogenous
substrate disposition and protection from xenobiotics (Jonker et al.,
2005; Noguchi et al., 2009; Robey et al., 2009). In the liver, MXR is
highly expressed on the canalicular membrane, where it transports
substrates and their conjugates into the bile, increasing their elimination
from the body (Maliepaard et al., 2001). Susceptibility to drug-induced
side effects has been linked to hepatic MXR expression and coding and
noncoding single nucleotide polymorphisms in ABCG2, the gene
encoding MXR (Poonkuzhali et al., 2008; Mo and Zhang, 2012;
Prasad et al., 2013). Therefore, understanding the mechanisms regulat-
ing hepatic expression of MXR is necessary to elucidate individual
susceptibility to cancer progression and drug side effects.
ABCG2 expression varies between tissues (Maliepaard et al., 2001)
and has significant tissue-specific variability, including in intestine
(Zamber et al., 2003; Urquhart et al., 2008), liver (Poonkuzhali et al.,
2008), and blast cells (Ross et al., 2000). The ability to alter phase I–III
expression in response to xenobiotic or toxin exposure is an important
mechanism for detoxification. ABCG2 expression is altered by many
stimuli, including hypoxia (Cheng and To, 2012), inflammation
(Pradhan et al., 2010), hormones (Zhang et al., 2006; Wang et al., 2008),
and nutrients (Lemos et al., 2008, 2009). Additionally, ABCG2
expression is modulated by nuclear receptor ligands including rifampin
and estrogen (Ee et al., 2004; Jigorel et al., 2006), indicating that several
enhancer elements are important for altering ABCG2 expression in
different contexts. Nuclear response elements (NREs) in the proximal
promoter of ABCG2 contribute minimally to ABCG2 expression since
the methylation of a CpG island over the ABCG2 promoter blocks the
access of nuclear receptors to their recognition sequence (Wiench et al.,
2011; Mo and Zhang, 2012). Additionally, nuclear receptors prefer
binding to cis-elements over proximal promoters (Wiench et al., 2011),
making cis-elements important for nuclear receptor response. With the
availability of genetic and tissue expression databases, the ability to
interpret and correlate expression data to genetic variation and drug
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response or toxicity depends on the identification of constitutive and
inducible regulatory elements (Smith et al., 2012). The studies described
here test the hypothesis that there are cis-regulatory elements in the
human ABCG2 gene locus that are active in vivo and aim to identify and
characterize those regulatory regions both in vitro and in vivo.
Liver-specific enhancers of transporter genes, such as ABCB11 and
SLCO1A2, have been identified by analysis of the evolutionary
conservation and prediction of conserved transcription factor binding
sites (TFBSs) (Pennacchio et al., 2007; Kim et al., 2011). Studies have
focused on sequence conservation of noncoding regions because many
developmental enhancers, tissue-specific enhancers and nuclear receptor
response elements are unchanged through different species (Ahituv
et al., 2004; Woolfe et al., 2005; Pennacchio et al., 2006, 2007; Loots,
2008; So et al., 2008). However, not all enhancer regions are conserved
(King et al., 2007). Since cis-regulatory elements contain binding sites
for multiple transcription factors, nonconserved regulatory elements
could be identified by transcription factor clusters (So et al., 2007;Wang
et al., 2007; Weltmeier and Borlak, 2011). Thus, identifying cis-
regulatory elements, especially for tissue-specific absorption, distribu-
tion, metabolism, and excretion genes, could be achieved by combining
complementary genomic data sets that include evolutionary conserva-
tion and both conserved and nonconserved TFBS clusters.
In this study, putative cis-regulatory elements in the ABCG2 locus
were identified by layered in silico analysis incorporating conserved
sequence and TFBS predictions, combined with the clustering of
nonconserved TFBSs. Regionswith predictions for, or ChIP-seq evidence
of, hepatic-specific transcription factor binding were prioritized. Putative
regulatory regions were cloned into enhancer or suppressor luciferase
vectors, which were previously validated for the identification of
clinically correlated human liver enhancer variants (Kim et al., 2011;
Matsson et al., 2012), and their activity was assayed in transiently
transfected cell lines of liver, kidney, intestine, and breast origin. Positive
in vitro enhancer elements were screened for in vivo liver-enhancer
activity through hydrodynamic tail vein injection adapted for liver-
enhancer screening (Liu et al., 1999; Kim et al., 2011; Kim and Ahituv,
2013). TheABCG2RE9-positive in vivo enhancer element and additional
enhancers with predicted nuclear receptor binding were screened for their
response to 17b-estradiol (E2) or rifampin. Identified in vivo enhancers
and in vitro suppressors in the ABCG2 gene locus could be involved in
tissue-specific or nuclear receptor–dependent expression of ABCG2.
Materials and Methods
Chemicals and Materials. The vectors pGL4.23 [luc2/minP], pGL4.74
[hRluc/TK], pGL4.13 [luc2/SV40], pGL3-promoter [luc+/SV40], pGL4.11b
[luc2P], and the Dual-Luciferase Reporter Assay System were purchased from
Promega (Madison, WI). The human embryonic kidney (HEK293T/17), colo-
rectal carcinoma (HCT116), hepatocellular carcinoma (HepG2), and breast
adenocarcinoma (MCF-7) cell lines were purchased from the American Type
Culture Collection (Manassas, VA). High-glucose Dulbecco’s modified Eagle’s
medium, Opti-Minimal Essential Medium, and Lipofectamine 2000 were
purchased from Invitrogen (Carlsbad, CA). Dimethylsulfoxide (DMSO), peni-
cillin, and streptomycin were purchased from the University of California, San
Francisco, Cell Culture Facility (San Francisco, CA). XhoI, Acc65I, NheI, and
HindIII were purchased from New England BioLabs (Ipswich, MA). Rifampin,
E2, placental genomic DNA, and 10% charcoal-stripped fetal bovine serum (FBS)
were all purchased from Sigma-Aldrich (St. Louis, MO). FBS (Axenia BioLogix,
Dixon, CA), GenElute HP Endotoxin-Free Maxiprep Kits (Sigma-Aldrich),
Improved Minimum Essential Medium without phenol red (Mediatech Inc,
Manassas, VA), PolyJet DNA In Vitro Transfection Reagent (SignaGen
Laboratories, Rockville, MD), TransIT EE In VivoGene Delivery System (Mirus
Bio, Madison, WI), CD1 mice (Charles River Laboratories, Wilmington, MA),
and PfuTurbo DNA Polymerase (Agilent Technologies, Santa Clara, CA) were
purchased from the indicated manufacturers. The CYP3A4 xenobiotic responsive
enhancer module (XREM) (Goodwin et al., 1999) in the pGL4.23 [luc2/minP]
vector and human pregnane X receptor (PXR) plasmid (hPXR)-pcDNA3.1 were
a gift from Kathy Giacomini (University of California, San Francisco, San
Francisco, CA).
In Silico Analysis of the ABCG2 Locus. The ABCG2 gene locus, defined as a
;300,000-base pair (bp) region stretching one gene upstream (PPM1K) and
downstream (PKD2) ofABCG2 (chr4:88911376-89220011, hg19), was scanned for
regions .100 bp and $70% conservation of human to mouse using the
Evolutionary Conserved Region (ECR) and Vista browsers (Frazer et al., 2004;
Ovcharenko et al., 2004). Conservation alignments from the ECR Browser were
submitted to rVista for the identification of conserved TFBSs using all vertebrate
transcription factor matrices from TRANSFAC professional (Wingender et al.,
2000; Loots and Ovcharenko, 2004). Regardless of conservation, the ABCG2 locus
was examined for cluster regions of predicted TFBSs, using the default setting of the
Cister program (Frith et al., 2001). Cister matrices used included preprogrammed
matrices (TATA, Sp1, CRE, estrogen response element (ERE), Nf-1, E2F, Mef-2,
Myf, CCAAT, AP-1, Ets, Myc, GATA, LSF, SRF, and Tef) and several additional
matrices obtained from TRANSFAC for nuclear receptors, hepatocyte nuclear
factors (HNFs), and HNF forkhead homologs (Supplemental Table 1) (Wingender
et al., 2000). Regions consisting of repeat coding elements or gene promoters were
eliminated from further analysis, and overlapping regions from the conservation and
Cister plot analyses were combined into single putative regulatory regions.
The top 30 putative regulatory regions were determined based on their
percentage of identity from human to mouse, the number of predicted TFBSs per
length of region, and the total number of TFBSs, with extra weight given to
TFBSs associated with ABCG2 and liver or kidney gene expression (Supple-
mental Table 1). Extra weight was also given to regions with ChIP-seq data
supporting the association with transcription factors, histone 3 lysine 27 acetyla-
tion, histone 3 lysine 4 methylation, and DNaseI sensitivity from TRANSFAC
and the Encyclopedia of DNA Elements (ENCODE) databases (Wingender et al.,
2000; ENCODE Project Consortium, 2011).
Cloning of Putative Regulatory Elements. Primerswere designed for the top
30 putative regulatory regions with extensions added for the restriction sites
Acc65I (forward primers) and XhoI (reverse primers) for all regions except
ABCG2RE1, for which NheI (forward primer) and HindIII (reverse primer) were
used, to ensure that the antistrand sequence of the enhancer element would be
oriented in the same manner as the element is to the ABCG2 promoter
(Supplemental Table 2). The region of interest was amplified from human
placenta genomic DNA using PfuTurbo DNA polymerase, gel purified, and
cloned into the pGL4.23 luciferase vector. Endotoxin-free DNA for the selected
enhancer plasmids, empty pGL4.23, ApoE-pGL4.23 (Simonet et al., 1993),
pGL3-promoter with and without suppressor elements, pGL4.11b with and
without the ABCG2 promoter, pGL4.13, hPXR-pcDNA3.1, and pGL4.74 vectors
(Supplemental Table 3) were isolated using the GenElute HP Endotoxin-Free
Maxiprep Kit following the protocol of the manufacturer. For follow-up studies
on suppressive elements, regions were reamplified from the pGL4.23 vectors and
cloned, using the same restriction sites, into the pGL3-promoter vector. Plasmids
were sequenced to verify their identity and orientation in the luciferase vectors.
Cell Culture and Transfections. HEK293T/17, HCT116, and HepG2 cell
lines were grown in high-glucose Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS, 100 U/mL penicillin, and 0.1 mg/mL streptomycin.
The MCF-7 cell line was grown in Improved Minimum Essential Medium
without phenol red, supplemented with 10% FBS, 100 U/mL penicillin, and
0.1 mg/mL streptomycin; for use in the nuclear receptor ligand assays, the 10%
FBS was charcoal stripped. All cell lines were grown in a 5% CO2 incubator at
37C. For the in vitro luciferase assays, the HEK293T/17, HepG2, and HCT116
cells were seeded into a 96-well plate at 1.8 104 cells/well and transfected when
they reached 80% confluency with 0.5 mL of Lipofectamine 2000 mixed with
80 ng of plasmid DNA (pGL4.23, Enhancer-pGL4.23, pGL3 promoter,
Suppressor-pGL3 promoter,ApoE-pGL4.23, or pGL4.13) plus 20 ng of pGL4.74,
following guidelines suggested in the protocol of the manufacturer. MCF-7 cells
were seeded at 2.5  104 cells/well and transfected once they reached 95%
confluency with 75 ng of ABCG2 plasmid, 25 ng of pGL4.74, and 0.4 mL of
PolyJet DNA In Vitro Transfection Reagent following the protocol of the
manufacturer. Cells were lysed with passive lysis buffer 18–24 hours after
transfection and measured for firefly and Renilla luciferase activity using the
Dual-Luciferase Reporter Assay System in a GloMax 96microplate Dual Injector
Luminometer (Promega) following the protocol of the manufacturer. Each
In Vivo Enhancers in the Human ABCG2 Locus 209
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experiment also included the empty pGL4.23 or pGL3-promoter vector as the
negative control and theApoE-pGL4.23 or pGL4.13 vector as the positive control.
The activity for each plasmid was calculated as the ratio of its normalized firefly
activity to that of the empty vector.
Mouse Hydrodynamic Tail Vein Enhancer Assay. Positive in vitro
enhancer elements were screened for in vivo liver enhancer activity using the
mouse hydrodynamic tail vein injection adapted for enhancer element screening
(Liu et al., 1999; Kim et al., 2011; Kim and Ahituv, 2013). Each plasmid was
injected into the tail vein of four to five mice using the TransIT EE In Vivo Gene
Delivery System following the protocol of the manufacturer. Briefly, 10 mg of
pGL4.23 vector with or without enhancer element, or the ApoE-positive control
liver enhancer (Simonet et al., 1993), along with 2 mg of pGL4.74 were injected
into the tail vein of male CD1 mice (Charles River Laboratories). After 24 hours,
micewere euthanized, and their livers were harvested and homogenized in passive
lysis buffer, followed by centrifugation at 4C for 30 minutes at 21,000g. The
supernatant was diluted 1:20 with lysis buffer andmeasured for firefly andRenilla
luciferase activity using the dual-luciferase reporter assay system according to the
protocol of the manufacturer in a Synergy 2 (BioTek Instruments, Winooski, VT)
microplate reader. The enhancer firefly activity was normalized to the Renilla
activity and expressed as fold activation relative to pGL4.23. All mouse work was
performed following a protocol approved by the University of California, San
Francisco, Institutional Animal Care and Use Committee.
Nuclear Receptor Ligand Treatment. The rifampin and E2 assays were
adapted from previously published protocols (Goodwin et al., 1999; Chen et al.,
2004; Ee et al., 2004; Wang et al., 2006; Tan et al., 2011). A plasmid with the
XREM region that induces CYP3A4 expression upon rifampin treatment and an
ABCG2 promoter construct that includes a known ERE were used as positive
controls (Goodwin et al., 1999; Chen et al., 2004; Ee et al., 2004; Wang et al.,
2006; Tan et al., 2011). HepG2 cells were transiently transfected as above with
pGL4.23, Enhancer-pGL4.23, or XREM-pGL4.23 and cotransfected with hPXR-
pcDNA3.1. Cells were treated for 24 hours with 25 mM rifampin or 0.1% DMSO
before being assayed for luciferase activity. MCF-7 cells were transiently
transfected as above with pGL4.23, Enhancer-pGL4.23, ABCG2 promoter-
pGL4.11b, or pGL4.11b. Cells were treated for 48 hours with 100 nM E2 or
0.2% DMSO before being assayed for luciferase activity.
Statistical Analysis. Putative enhancer elements were considered to have
statistically significant enhancer activity over the empty pGL4.23 vector
activity if the analysis of variance (ANOVA) analysis, followed by a Bonferroni
multiple comparison t test, had a P value ,0.05 in each replicate experiment
(three to six wells per plasmid). Elements with significant enhancer activ-
ity.1.6-fold above the empty vector were chosen for follow-up in vivo testing.
For analysis of in vivo results, normalized enhancer activity from four to five
mice per plasmid was compared with the empty pGL4.23 vector using a
Student’s t test and was considered positive in vivo at P, 0.05. Constructs were
chosen for in vitro suppressor follow-up in the pGL3-promoter vector if they
exhibited a 75% reduction in luciferase activity from empty vector in one cell
line and at least a 50% reduction in an additional cell line. Results from each
transfection (5–10 wells per plasmid) were analyzed with an ANOVA followed
by a Bonferroni multiple comparison t test to compare suppressor constructs to
the empty pGL3-promoter vector with significance determined if the P value
was,0.05. All statistics were run using GraphPad Prism 5 software (GraphPad,
San Diego, CA).
Results
Identification of High-Priority Putative cis-Regulatory Elements.
A list of 30 high-priority elements (Table 1) was generated by the
in silico analysis of the ABCG2 gene locus. Figure 1 illustrates a
snapshot of evolutionary conservation, the clustering of predicted cis-
elements from Cister plot and ChIP-seq data available from ENCODE
and TRANSFAC databases (Wingender et al., 2000; Frith et al., 2001;
ENCODE Project Consortium, 2011). There were five regions that
appeared in both the evolutionary conservation and Cister plot analyses,
all of which were tested for enhancer activity. Also included were
regions with preliminary ENCODE ChIP-seq data; for example,
ABCG2RE8 had FOXA1 and GATA3 peaks in T-47D cells and p300
peaks in HeLa cells, and ABCG2RE23 had CTCF peaks in many cell
lines, including HepG2 (Supplemental Fig. 1). The high-priority
putative enhancer elements were located throughout the ABCG2 gene
locus and ranged from 174 to 1909 bp (Table 1). These regions were
screened for in vitro enhancer activity.
TABLE 1
High-priority putative liver enhancer regions in the ABCG2 locus
nt, not tested.
1Enhancer activity in pGL4.23 (unshaded) or suppressor activity in pGL3-promoter (shaded)
expressed as the ratio of firefly to Renilla luciferase activity and normalized to the empty vector
(pGL4.23 or pGL3-promoter). Values are the mean activities from a representative experiment
with three to five wells/plasmid.
↑Activity is significantly increased after treatment with rifampin (HepG2).
*P , 0.05
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In Vitro Enhancer and Suppressor Identification. The 30 high-
priority putative enhancer elements (Table 1) were transiently trans-
fected into HepG2 (liver) cell lines, and their luciferase activity was
quantified. Cells were cotransfected with Renilla as a transfection
control, and in each experiment the empty vector (pGL4.23) and the
pGL4.13-positive control vector were also transfected as a negative and
positive control, respectively. The pGL4.13 vector had .1000-fold
activity over the pGL4.23 vector (Fig. 2). Enhancers were binned
according to their “strong” ($4-fold activation), moderate (2- to 4-fold
activation) and weak (1.5- to 2-fold activation) enhancer activities. Five
regions had significant enhancer activity in the HepG2 cell line, with
ABCG2RE6 having the strongest HepG2 enhancer activity (Fig. 2). The
ABCG2RE9, ABCG2RE22, and ABCG2RE26 regions had moderate
enhancer activity. The ABCG2RE14 region had weak enhancer activity.
Since these elements have the potential to be enhancers in other tissues,
they were also screened in HEK293T (kidney), HCT116 (intestine), and
MCF-7 (breast) cell lines (Supplemental Fig. 2; Supplemental Table 2).
Interestingly, the strongest enhancer in HepG2 cells (ABCG2RE6) was
also the strongest enhancer in renal, intestinal, and breast cells. The
ABCG2RE22 and ABCG2RE26 moderate liver enhancers also showed
moderate to high enhancer activity in HEK293T cells. Based on HepG2
data, five regions with significantly increased enhancer activity .1.6-
fold warranted in vivo follow-up. From the collective data across all of
the cell lines, an additional four putative enhancer elements were also
tested for in vivo activity.
Many of the 30 regions analyzed in the enhancer screen showed a
significant decrease in luciferase activity (Fig. 2; Supplemental Fig. 2;
Table 1). Nine regions exhibited a 75% decrease in luciferase activity in
one cell line and at least a 50% decrease in two additional cell lines, and
these were selected for follow-up in a suppressor assay. The ABC-
G2RE30 region, which was suppressive in two cell lines, was also
chosen for follow-up because it exhibited enhancer activity in the renal
cell line. HepG2 suppressor activity for 4 of 10 selected regions was
confirmed by cloning into the pGL3-promoter vector, transfecting into
Fig. 1. Snapshot from ABCG2 locus illustrating representative results from bioinformatic analyses. Red boxes indicate high-priority putative cis-regulatory regions that were
chosen for further study based on conservation as determined by the Vista Browser (A); UCSC (University of California, Santa Cruz) Genome Browser mammal basewise
conservation (C); or ECR browser conservation to fish, possum, mouse, canine, and monkey (D). Regions were also chosen based on clusters of transcription factor elements
determined by Cister plot and overlap of these regions (E) with ENCODE DNaseI, ChIP-seq, and conserved TFBS data (B).
Fig. 2. Activity of putative hepatic enhancer elements in vitro. Luciferase activity
was measured in the transiently transfected liver (HepG2) cell line. Enhancer activity
is expressed as the ratio of firefly to Renilla luciferase activity normalized to the
empty vector activity (pGL4.23). ECRs are displayed respective to their genomic
orientation. Data are expressed as the mean 6 SEM from a representative
experiment (n = 3 wells per plasmid). Differences between putative enhancer
elements and empty vector were tested by an ANOVA followed by a post hoc
Bonferroni multiple comparison t test: ***P , 0.0001, **P , 0.001.
In Vivo Enhancers in the Human ABCG2 Locus 211
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the HepG2 cell line, and measuring the resulting luciferase activity
relative to empty vector (Fig. 3). pGL3-promoter is a firefly luciferase
vector that is designed to accept a putative suppressor element upstream
of the strong SV40 promoter; without a suppressor, this promoter drives
strong expression of luciferase. Since regions could potentially have
tissue-specific suppressor activity, they were also screened in kidney,
intestinal, and breast cell lines. ABCG2RE7 was the strongest and most
consistent suppressor, with a .75% decrease in luciferase activity in
HepG2 and HCT116 cells. In HEK293T andMCF-7 cells, ABCG2RE7
also had a .50% decrease in luciferase activity (Supplemental Fig. 3).
The ABCG2RE11, ABCG2RE29, and ABCG2RE30 also had signifi-
cant suppressor activity in the HepG2 cell line. Eleven genomic regions
(37%) showed enhancer activity, and 7 showed suppressor activity
(23%) in at least one of the four cell lines, including ABCG2RE30,
which had enhancer activity in HEK293 cells and suppressor activity in
the HepG2 and HCT116 cell lines. Thus, a total of 17 regions (57%) had
significant regulatory activity in vitro.
In Vivo Enhancer Activity. The five HepG2 in vitro enhancers were
tested for in vivo activity in mice using the hydrodynamic tail vein
injection technique (Kim and Ahituv, 2013). The ApoE liver enhancer
(Simonet et al., 1993; Kim et al., 2011), previously shown to be a strong
enhancer in vivo and an effective control for the hydrodynamic tail vein
injection, had .40-fold enhancer activity (Fig. 4). Of the five HepG2
enhancer elements tested in vivo, four of them had significant enhancer
activity (Fig. 4, Table 1), giving an 80% rate of positive in vivo activity
when picking enhancers based on in vitro HepG2 enhancer activity. The
ABCG2RE6 was the weakest enhancer in vivo, showing 2.45-fold
activation. ABCG2RE14 and ABCG2RE26 had ;7-fold relative
enhancer activation. Of the HepG2 putative elements, ABCG2RE9
was the strongest in vivo enhancer. Two of an additional four regions,
screened in vitro based on their activity in other cell lines and predicted
or ChIP-seq evidence of hepatic transcription factor binding, also had
positive enhancer activity (Supplemental Fig. 4). Overall the strongest
in vivo enhancer was the ABCG2RE1 region; it had consistent
activation .120-fold, which is almost three times that of the positive
ApoE control.
Nuclear Receptor Ligand Response. The ability of ABCG2RE9
activity to respond to the PXR ligand rifampin or an estrogen receptor
(ER) ligand E2 was tested in transiently transfected HepG2 and MCF-7
cells, respectively. ABCG2RE9 had a 3-fold induction of its basal
enhancer activity with rifampin treatment (Fig. 5A; Table 1). The basal
transcriptional activity of the ABCG2RE9 region was reduced ;50%
upon treatment with E2 (Fig. 5B; Table 1). Additionally, eight regions
with both in vitro enhancer activity in at least one cell line and
bioinformatic evidence that either PXR or ER were bound to it (data not
shown) were tested for their response to rifampin and E2. One additional
enhancer region was responsive to rifampin, and three showed altered
activity in response to E2 (Supplemental Fig. 5).
Transcription Factor Binding via ChIP-Seq. The ABCG2RE9
enhancer has extensive transcriptional marks in ENCODE, including
histone 3 lysine 4 methylation, DNaseI sensitivity clusters, and many
transcription factor ChIP-seq peaks in HepG2, including HNF4a,
HNF4g, retinoid X receptor (RXR), and p300 (Fig. 6). Specifically
for these studies, FOXA1, a dimer partner of ER and RXRa, binds to
ABCG2RE9. A ChIP-seq experiment by our laboratories (Smith et al.,
2014) showed that p300 binds ABCG2RE9 in human primary hepato-
cytes treated both with and without rifampin, providing strong evidence
that this is a transcriptionally active region in human liver (Fig. 6). The
ABCG2RE8 and ABCG2RE23 putative enhancer elements also have
ENCODE ChIP-seq data supporting transcription factor binding to these
regions (Supplemental Fig. 1).
Discussion
These studies provide strong evidence in support of ABCG2RE9 as a
nuclear receptor responsive element and cis-regulatory enhancer. Aside
from NREs in the ABCG2 proximal promoter, very little is known about
the transcriptional regulation of ABCG2. Regulatory control of MXR
expression gives cells the ability to adapt to elevated or reduced levels of
substrates. The identification of tissue-specific cis-regulatory elements
of ABCG2 could have implications for ABCG2 variation within those
tissues and link clinical phenotypes with noncoding genetic variants. In
the liver, MXR effluxes its substrates into the bile, where altered hepatic
expression would affect drug elimination and thus pharmacokinetics.
Characterizing hepatic regulation of ABCG2 is important in understand-
ing how expression impacts both systemic and target site drug exposure.
In the present study, regulatory elements in the ABCG2 gene locus
were identified and characterized through in silico, in vitro, and in vivo
Fig. 3. Activity of putative hepatic suppressor elements in vitro. Luciferase activity
of selected regions cloned into the pGL3-promoter vector and transiently transfected
into the liver (HepG2) cell line. Suppressor activity is expressed as the ratio of firefly
to Renilla luciferase activity normalized to the empty vector activity (pGL3-
promoter). Data are expressed as the mean 6 SEM from a representative experiment
(n = 5 wells per plasmid). Differences between putative suppressor elements and
empty vector were tested by an ANOVA followed by a post hoc Bonferroni multiple
comparison t test: ***P , 0.0001, **P , 0.001.
Fig. 4. In vivo liver-enhancer activity in mice. Luciferase activity in liver
homogenates was measured 24 hours after plasmid injection into the tail vein of
mice. Enhancer activity is expressed as the ratio of the firefly to Renilla luciferase
activity normalized to the empty vector activity (pGL4.23). Data are expressed as the
mean 6 SEM for four to five mice. Differences between enhancer elements and
empty vector were tested by an unpaired Student’s t test; *P , 0.05. The ApoE
construct was injected as a positive control liver-specific enhancer (Kim and Ahituv,
2013).
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methods. Through our in silico analysis, considering DNA and TFBS
conservation between human and mice, transcription factor clustering,
and ChIP-seq data, we chose 30 high-priority putative regulatory regions
to test for cis-regulatory activity. Starting from in silico predictions, five
regions had enhancer activity and four regions had suppressor activity in
the HepG2 cell line; overall, nine regions (30%) were identified with
in vitro human hepatic regulatory activity. Besides the liver, MXR has
variable expression in other tissues (Maliepaard et al., 2001), so it is
possible that these regions have tissue-specific enhancer activity. When
screened in additional cell lines, six more in vitro enhancers and three
additional suppressors were identified.
The in vitro assays allowed the use of stringent criteria for selecting
enhancer elements for in vivo follow-up. Based on cumulative cell line
data, nine regions were screened in the in vivo hydrodynamic tail vein
assay, and six regions (67%) had positive in vivo enhancer activity.
Importantly, 80% (four of five regions) of the positive enhancer regions
in HepG2 cells in vitro were confirmed as in vivo liver enhancers,
suggesting a strong correlation between enhancer activity in human liver
cell lines and mouse hepatic tissue. This high correlation may be bi-
ased by the use of DNA conservation and the presence of conserved
consensus sequences from mouse to human as important selection
criteria, and may miss human-specific regulatory elements. Of the
30 regions identified for characterization in vitro, 6 (20%) were positive
in vivo liver enhancers. The in vivo success rate was 2-fold higher than a
previous in vivo liver membrane transporter enhancer screen that used
conservation and liver-specific TFBSs as screening criteria, suggesting
that the addition of in vitro cell-based screening or consideration of
ChIP-seq data could improve the selection process for in vivo enhancer
assays (Kim et al., 2011). In general, enhancer activity in nonhepatic
cells was not predictive of in vivo liver regulatory activity; one exception
Fig. 6. ABCG2RE9 ChIP-seq peaks in human cell lines and hepatocytes. UCSC (University of California, Santa Cruz) Genome Browser snapshot of p300 ChIP-seq data
from rifampin- and DMSO-treated hepatocytes (Smith et al., 2014) and ENCODE ChIP-seq data (ENCODE Project Consortium, 2011) within ABCG2RE9. The cell lines in
which each of the peaks from ENCODE were found are identified as follows after each bar: A549 (A), HeLa (H), K562 (K), HepG2 (L), NB4 (n), and SK-N-HS with retinoic
acid (S). Intensity of signal is indicated by the shade of gray, with black being the strongest. Green arrow boxes indicate the presence of a consensus motif for respective
transcription factor. Transcription factors of note include FOXA1 (ER partner), NR3C1 (glucocorticoid receptor), HNF4a, HNF4g, and RXRa, and p300.
Fig. 5. Effect of rifampin and E2 treatment on ABCG2RE9 enhancer activity.
Luciferase activity of regulatory elements in transiently transfected liver (HepG2)
cells 24 hours after 25 mM rifampin treatment and cotransfected with a human PXR
plasmid (hPXR-pcDNA3.1) (A) and in breast (MCF-7) cells (B) 48 hours after
100 nM E2 treatment. A known rifampin response element (XREM) and an ERE
(ABCG2 promoter) were used as positive controls (Goodwin et al., 1999; Chen et al.,
2004; Ee et al., 2004; Wang et al., 2006; Tan et al., 2011). Enhancer activity is
expressed as the ratio of firefly to Renilla activity in the presence of ligand to the
same ratio after DMSO treatment. Data are expressed as the mean 6 SEM from a
representative experiment (n = 6–8 wells per treatment). Differences between the
enhancer activity in the absence and presence of ligand were tested by an unpaired
Student’s t test: ***P , 0.0001, *P , 0.05.
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was the strongest in vivo liver enhancer (ABCG2RE1), which was
inactive in liver cells, but was active in kidney, intestine, and breast cell
lines.
In vivo liver-enhancer activity ranged from .120-fold activation
(ABCG2RE1), three times that of the positiveApoE control, to 2.45-fold
(ABCG2RE6); the remaining enhancers showed 5- to 16.5-fold relative
activation. This degree of activation is in the range of the strong enhancer
elements previously discovered for membrane transporters (Kim et al.,
2011). Three of the in vivo enhancers were within ABCG2 introns
[ABCG2RE8 (intron 10), ABCG2RE9 (intron 9), and ABCG2RE14
(intron 1)], which is consistent with the finding that 40% of enhancers
are within intronic regions (Heintzman et al., 2009). An in vivo enhancer
(ABCG2RE26) encompassing exon 4 of PPM1K was also identified.
Since exon 4 of PPM1K is relatively short, ABCG2RE26 was not
excluded from our analysis because it also had numerous conserved and
nonconserved predicted TFBSs (data not shown). There are other
examples of coding exons working as an enhancer to regulate the tissue-
specific expression of a neighboring gene that were identified though
ChIP-seq data sets (Birnbaum et al., 2012). However, these examples
have been infrequent, since in silico pipelines to identify conserved
enhancer elements often eliminate coding regions under the assumption
that they are conserved to preserve protein function, not due to cis-
regulatory activity. These data illustrate that the addition of TFBS
clustering, regardless of conservation or genomic region, could improve
the enhancer selection process.
To investigate the possible mechanisms driving the in vivo activity of
enhancers, the ENCODE and TRANSFAC databases were mined for
ChIP-seq data or predicted sites of transcription factor binding.
TRANSFAC analysis of ABCG2RE1 predicted binding sites for
constitutive androstane receptor, liver X receptor, PXR, vitamin D
receptor, and the aryl hydrocarbon receptor (data not shown). The
in vitro enhancer activity of ABCG2RE1 was increased by the PXR
ligand rifampin, indicating that it has both constitutive and inducible
enhancer activity. The ABCG2RE1 enhancer is ;4000 bp upstream of
the PKD2 promoter and could be regulating the expression of PKD2 or
be working as a loci enhancer element to regulate the expression of
PKD2, PPM1K, and/or ABGC2 in the kidney where they are all
expressed.
ENCODE analysis found ChIP-seq signals for many transcription
factors bound to the ABCG2RE9 region in liver cells, including RXRa
and HNF4a. Both transcription factors are important in liver gene
expression, and they interact with each other and with ERa (Lee et al.,
1998; Schrem et al., 2002; Germain et al., 2006). Although constitu-
tive androstane receptor and PXR cross talk with FOXA2 (another
transcription factor that binds ABCG2RE9) to regulate hepatic genes
(Konno et al., 2008), the presence of glucocorticoid receptor, FOXA1,
RXRa, and p300 ChIP-seq signals, and the current data showing that
ABCG2RE9 responds to both PXR and ER ligands, indicate a likely role
of this regulatory region in hormone response and possibly the
expression of ABCG2 in the intestine, liver, and placenta.
Some experiments in the ENCODE ChIP-seq database include before
and after treatment with nuclear receptor ligands, providing an excellent
resource for future regulatory element searches (ENCODE Project
Consortium, 2011). It is worth noting that not all of the regions with
ChIP-seq data were enhancers. ABCG2RE23, for example, has many
ChIP-seq peaks, especially strong and reproducible signals for CTCF
(data not shown), but showed neither enhancer nor suppressor activity in
most of the cell lines. This could be because CTCF can act as a general
transcription factor, but it is best characterized for its ability to act as an
insulator and modulator of chromatin structure (Phillips and Corces,
2009). The in vivo enhancer with highest activity, ABCG2RE1, was
devoid of ChIP-seqmarks, but many transcription factors have either not
been characterized or do not have reliable antibodies for use in ChIP-seq
experiments, thus restricting the interpretation of data in ENCODE.
ManyNREswork in coordination with other transcription factors, like
p300, to remodel chromatin, and the chromatin context is extremely
important to transcription factor activity (Wiench et al., 2011). Without
the complex chromatin context, which was not assayed in our study, and
the possibility that certain transcription factors are absent in the stud-
ied cell lines, some of the putative regions could still be in vivo cis-
regulatory elements. This is most evident from the results of the
ABCG2RE1 regulatory region, which had weak activity in vitro yet the
strongest activity in vivo. Similarly, ABCG2RE6 had strong in vitro
activity yet weak activity detected in vivo. Other limitations of the
hydrodynamic tail vein assay include discordance between mouse and
human TFBSs, inability to detect nuclear factor response elements
without the ligand present, and the limited ability to detect enhancer
activity outside the liver. Additional induction assays would be needed
to detect regulatory elements that are active only with drug treatment,
and the evaluation of enhancer regions in other model systems such as
zebrafish might be useful to confirm non–liver-enhancer activity.
Potential tissue-specific regulatory elements are highlighted in Supple-
mental Table 2. Although individual steps of the screening pipeline have
limitations, taken together they robustly identified several cis-regulatory
elements with in vivo liver enhancer activity in the ABCG2 gene locus
that are strongly supported by ChIP-seq data.
Through detailed in silico, in vitro, and in vivo cis-regulatory assays,
multiple regions in the ABCG2 gene locus that function as enhancers or
suppressors were identified. These regions have evidence for transcrip-
tion factor binding that link them with tissue-specific or nuclear receptor
responsive expression of ABCG2. Overall, ABCG2RE9 has the most
evidence supporting its role as a nuclear receptor responsive element and
cis-regulatory enhancer. It has constitutive hepatic activity in vitro and
in vivo, nuclear receptor–inducible activity in the human HepG2 cell
line, and binding of transcription factors determined by ChIP-seq in
human hepatocytes. These results indicate that computational genetics
coupled with in vitro and in vivo assays are capable of finding global and
liver-specific enhancers. With increasing evidence for the effects of cis-
regulatory regions on drug disposition and efficacy (Smith et al., 2012),
the identification of these elements can help to elucidate how genetic
variants in noncoding regions of the genome cause clinical variation in
drug transporter gene expression that result in altered pharmacokinetic
and pharmacodynamic properties.
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